FDA Approves First Targeted Drug against Cystic Fibrosis
The U.S. Food and Drug Administration today approved a new drug that tackles the underlying cause of cystic fibrosis (CF) in 4 percent of patients. The drug, called ivacaftor (brand name Kalydeco), acts by helping the body make better use of a protein that works incorrectly in cystic fibrosis patients. The underlying research behind this [...]
Keep reading »What’s in your gut? Microbiota categories might help simplify personalized medicine
April 20th, 2011 |
2
The diverse wilderness of life inside of our bodies is just starting to gain the attention of scientists. The human gut alone typically holds some 100,000 billion bitty bacteria, and with no two people’s microbiomes being the same, classifying these crucial organisms has been challenging. A new study, published online April 20 in Nature, proposes [...]
Keep reading »
Is the “war on cancer” winnable? 40 years after the unofficial declaration, the disease is spreading throughout the globe
March 24th, 2011 |
15
Pervasive, elusive and tough, cancer has proved to be a formidable foe against generations of bright and well-funded researchers. Although there was never an official declaration, military rhetoric became the cliché among journalists covering cancer research as President Nixon signed the U.S. National Cancer Act in December 1971. The "reconnaissance" might be completed in labs [...]
Keep reading »
See what we're tweeting about
